Our parent company China National Biotec Group (CNBG) is the 6th largest vaccine manufacturer in the world. CNBG has the capacity of manufacturing approximately 700 million doses of 50 various human vaccines annually.
Sino-Innovax is also committed to benefit people from all around the globe through our constant development of efficient and novel vaccines. Our Singapore pipeline includes enterovirus 71 vaccine (inactivated), quadrivalent influenza vaccine (inactivated), varicella vaccine (live attenuated) and more.
Plasma-derived products are crucial, life-saving therapies for a huge range of rare and complex conditions such as bleeding disorders and inhibitor deficiencies. Sino-Innovax is in a unique position to offer expertise, technologies and finalized products in response to the growing global demand.
Beijing Tiantan Biological Products is our partner for plasma collection network and an industry leader in plasma derived products with more than 50 apheresis collection bases in 13 provinces and autonomous regions across china. We offer three major categories of products: human albumin, human immunoglobulin, and human coagulation factor VIII with a total of 14 varieties. The pipeline further expands to human serum albumin, tetanus, rabies and hepatitis B human immunoglobulins.
The COVID-19 pandemic has underscored the importance of research and development in preparation for future pandemics. In Sino-Innovax, we focus on predicting new infectious landscapes and challenge the frontiers of vaccine science. We are open to collaboration with innovative and cutting-edge technologies and products which align with our strategic interest.
